Trial Profile
Clinical trial of NX 1207 in patients with liver cancer.
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 16 May 2012
Price :
$35
*
At a glance
- Drugs Fexapotide (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Nymox Pharmaceutical Corporation
- 16 May 2012 Nymox is still planning to conduct clinical trials of NX 1207 in patients with liver cancer.
- 01 Apr 2010 New trial record